Kinetics of Recovery of Naïve and Memory T Cells in Acute Leukemia Patients after Allogeneic Stem Cell Transplantation Depending on Different GVHD Prophylaxis Regimens

Natalia Popova[1], Mikhail Drokov[1], Yulia Davydova[2], Nikolay Kapranov[2], Vera Vasilieva[1], Irina Galtseva[2], Larisa Kuzmina[1], Elena Parovichnikova[1,2]

[1]Department of BMT, Immunotherapy and Post-BMT Complications Department, National Research Center for Hematology, Moscow, Russian Federation
[2]The Laboratory of Immunophenotyping of Blood and Bone Marrow Cells, National Research Center for Hematology, Moscow, Russian Federation

Corresponding Author: Mikhail Drokov, Department of BMT, Immunotherapy and Post-BMT Complications Department, National Research Center for Hematology, Moscow, Russian Federation
Email: mdrokov@gmail.com

ABSTRACT
Background: Memory T cells are a heterogeneous population of immune cells that provide adaptive immunity. Its full recovery seems essential for graft-versus-tumor reactions that provide an opportunity for biological cure in patients with acute leukemia. The use of mismatched or haploidentical donors has increased, which has become possible because of modifications in graft versus host disease (GVHD) prophylaxis.
Materials and Methods: Sixty-five leukemia patients (acute myeloid leukemia – 40, acute lymphoblastic leukemia – 25), median age 33 (17–61) years, underwent allo-HSCT from 2016 to 2019 in the National Research Centre for Hematology. Patients were divided into three groups based on the impact of GVHD prophylaxis on T cell recovery: horse antithymocyte globulin (ATG)-based regimen (n=32), horse ATG combined with posttransplant cyclophosphamide (PT-Cy) (n=18), and *ex vivo* T cell depletion (n=15).
Results: The early period after transplantation (before day +100) was characterized by significantly lower absolute numbers of T naïve, memory stem and T central memory cells in peripheral blood in patients after ATG+PT-Cy-regimen or ex vivo T cell depletion than after ATG-based prophylaxis (p<0.05). Moreover, strong depletion of naïve T and memory stem cells prevents the development of GVHD, and determining the absolute number of CD8$^+$ naïve T and memory stem cells with a cutoff of 1.31 cells per microliter seems to be a perspective in assessing the risks of developing acute GVHD (p=0.008). The dynamics of T cell recovery showed the involvement of either circulating or bone marrow resident T effector cells shortly after allogeneic transplantation in all patients, but the use of manipulated grafts with *ex vivo* T cell depletion requires the involvement of naïve and memory stem cells. There was no significant effect of T cell recovery on leukemia relapse after allogeneic transplantation.
Conclusion: These experimental outcomes contribute to providing the best understanding of immunological events that occur early after transplantation and help in the rational choice of GVHD prophylaxis in patients who will undergo allogeneic transplantation. Our study demonstrated the comparable immunological effects of posttransplant cyclophosphamide and *ex vivo* T cell depletion and immunological inefficiency of horse ATG for GVHD prevention**.**

Keywords: GVHD prophylaxis; Immune reconstitution; T memory cells; Post-transplant cyclophosphamide; T cell depletion; Horse ATG

INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a method to achieve durable remission and potentially full recovery in adults with acute leukemia. Its effect is based on the transfer of the immune system from the donor to the recipient,

which triggers a graft-versus-leukemia response (GVL). However, prolonged immunodeficiency after allo-HSCT is associated with various infections, and the delays or inadequacy in immune reconstitution determine posttransplant complications such as graft versus host disease (GVHD), leukemia relapse, or secondary tumors[1-3].

Different immune cells recover differently after allo-HSCT. The reconstitution of innate immunity occurs rapidly during the first month after allo-HSCT, but the full recovery of adaptive immunity that provides anti-infectious and antitumor protection takes several years[3]. Moreover, conditioning regimens and GVHD prophylaxis influence immune cells and their recovery kinetics. The choice of therapy is significant and determines the course of the posttransplant period [4-6]. The recovery of T cell immunity takes approximately 1 year after allo-HSCT; humoral immunity requires more than 2 years[3]. In this research, we focused on T cell reconstitution after allo-HSCT.

The early posttransplant period is characterized by the thymus-independent pathway of T cell recovery involving the proliferation of mature donor T cells that were transplanted to the patient together with hematopoietic stem cells[7]. A distinctive feature of thymus-dependent reconstitution is the generation of de novo naïve T cells and the subsequent formation of a memory T cell pool [7, 8]. Immunological memory is characterized by a prompt reaction to foreign antigens and appears to be essential for GVL[9,10].

Immune reconstitution depends on many factors. Some factors are invariable, such as patient age, and others can be modified. For example, myeloablative conditioning (MAC) is associated with prolonged immune restoration [11, 12]. The literature has reported that total body irradiation or high-dose busulfan causes irreversible death of epithelial cortical thymic cells, leading to the impossibility of forming new lymphoid populations[13,14]. Reduced intensity conditioning (RIC) is significantly less damaging to thymic cells than MAC is [4, 15]. This was confirmed by the detection of recent thymic emigrants on day +90, whereas after MAC, these cells were not observed even on day +365 after allo-HSCT [16, 17].

The number of haploidentical transplantations (haplo-HSCT) has been increasing, which has facilitated the modification of GVHD prophylaxis protocols. Posttransplant cyclophosphamide (Post-Cy) on days +3 and +4 has been highly effective in many clinical studies [18, 19], and today, it has almost replaced other preventive regimens. Competitive GVHD prophylaxis based on *in vivo* T cell depletion is the regimen with antithymocyte globulin (ATG)[20,21]. Many studies have demonstrated the impact of Post-Cy and ATG on immune recovery and the advantages of Post-Cy over ATG[22-24]. Another platform for GVHD prevention is *ex vivo* T cell depletion[25]. However, the use of this approach is limited to adults, and the results are controversial.

In this study, we compared the recovery of memory T cells as the main population providing adaptive immunity in patients with acute leukemia after allo-HSCT with different GVHD prophylaxis regimens (ATG-based versus ATG + Post-Cy versus *ex vivo* T cell depletion). We analyzed the impact of these GVHD prophylaxis regimens on T memory cell subsets in the short term after allo-HSCT and found an immunological basis for the rational choice of immunosuppressive therapy.

MTERIALS AND METHODS
Patient characteristics

This study assessed 65 patients with acute leukemia who underwent allo-HSCT between September 2016 and February 2019 at the National Research Center for Hematology, Moscow, Russia. The median patient age was 33 years (range, 17–61 years). Acute myeloid leukemia (AML) was diagnosed in 40 patients, and acute lymphoblastic leukemia (ALL) in 25 patients. Most patients (n=63) were confirmed to achieve complete remission (CR). Molecular relapse before the start of pretransplant conditioning was detected in two patients. Patient characteristics are presented in Table 1.

Table 1: Patient characteristics

Characteristics	Diagnosis (n=65)	
	AML (n=40)	ALL (n=25)
Median age	35 (18-60)	30 (17-61)
Sex (m/f), n	19/21	13/12
CR 1, n	31 (77.5%)	13 (52%)
Risk factors for CR 1:		
MRD before allo-HSCT	7/31 (22.6%)	6/13 (46.2%)
Primary-resistant disease	5/31 (16.1%)	1/13 (7.7%)
t (9;22)	–	8/13 (61.5%)
FLT3+	4 (12.9%)	–
t (8;21), MRD-persistent	3 (9.7%)	–
Complex karyotype	3 (9.7%)	–
CR >1, n	8 (20%)	11 (44%)
Molecular relapse, n	1 (2.5%)	1 (4%)

Conditioning regimens, type of allo-HSCT, and graft source

All patients underwent pretransplant conditioning. MAC was administered to 20 young patients, median age, 25 years (range, 17–41 years), who had no comorbidities. Classical MAC based on busulfan (12 mg/kg) and cyclophosphamide (120 mg/kg) (BuCy) was used in 12 of the 20 patients. Eight of the 20 patients underwent haplo-HSCT with *ex vivo* TCR αβ and CD 19 depletion and received thiotepa 10 mg/kg combined with treosulfan 42 g/m^2 and fludarabine 150 mg/m^2 (TreoThiotepaFlu). RIC was selected for 45 patients. The classical RIC protocol was fludarabine 180 mg/m^2 and busulfan 8 mg/kg (FluBu) and administered to 38 patients, and the regimen with treosulfan 42 g/m^2, melphalan 140 mg/m^2, and fludarabine 150 mg/m^2 (TreoMelFlu) was applied in case of haplo-HSCT with *ex vivo* TCR αβ and CD 19 depletion in 7 patients.

The detailed conditioning regimens are presented in Table 2.

Table 2. Conditioning regimens

Conditioning	Drug	Dose	Days
BuCy	Busulfan	4 mg/kg - oral in 4 doses (1 mg/kg) every 6 hours	-6 to -4
	Cyclophosphamide	60 mg/kg i.v. over an hour	-3 to -2
TreoThiotepaFlu	Thiotepa	5 mg/kg i.v. over 2 hours	-6 to -5
	Treosulfan	14 g/m^2 i.v. over 2 hours	-5 to -3
	Fludarabine	30 mg/m^2 i.v. over 30 min	-6 to -2
FluBu	Busulfan	4 mg/kg - oral in 4 doses (1 mg/kg) every 6 hours	-6 to -5
	Fludarabine	30 mg/m^2 i.v. over 2 hours	-10 to -5
TreoMelFlu	Treosulfan	14 g/m^2 i.v. over 2 hours	-5 to -3
	Melphalan	70 mg/m^2 i.v. over an hour	-3 to -2
	Fludarabine	30 mg/m^2 i.v. over 30 min	-6 to -2

Thirteen patients were transplanted from 10/10 matched donors (MRDs), 21 from haploidentical donors, 19 from matched 10/10 unrelated donors (MUDs), and 12 from mismatched 9/10 or 8/10 unrelated donors (MMUDs).

Bone marrow (BM) was used in 22 patients, and peripheral blood stem cells (PBSC) in 43 as the graft source.

GVHD prophylaxis

All patients were subdivided into three groups based on the GVHD prophylaxis regimen. Thirty-two patients (median age, 33 years; range, 20–61 years) received an ATG-based regimen including horse ATG, and the dosage was 10 mg/kg per day on days -4, -3, -2, and -1, combined with cyclosporin A (CsA), methotrexate (MTX), and mycophenolate mofetil (MMF). This regimen has been applied in cases of MRDs or MUDs transplantation.

Post-Cy at a dosage of 50 mg/kg per day on days +3 and +4 combined with horse ATG, CsA, and MMF was administered to patients who underwent allo-HSCT from unrelated mismatched donors or related haploidentical donors (n=18, median age of 36, range 23–58).

Fifteen patients with a median age of 20 (17-57) underwent haplo-HSCT with manipulated grafts. *Ex vivo* TCRαβ and CD19 depletion were performed to prevent GVHD. Rituximab 100 mg/m^2 on day -1, bortezomib 1.3 mg/m^2 per day on days -5, -2, +2, +5; Tocilizumab 8 mg/kg on day -; and Abatacept 10 mg/kg per day on days -1, +7, +14, +28 were used as additional immunosuppressive therapy in this group. Detailed GVHD prophylaxis and types of allo-HACT are presented in Table 3.

Table 3: Choice of GVHD prophylaxis and types of allo-HSCT

Type of allo-HSCT	GVHD prophylaxis	Drug	Dose	Days
MRD or MUD	ATG-based (n=32)	Horse ATG	10 mg/kg in 2 doses, i.v. over 6 hours	-4 to -1
		CsA	3 mg/kg in 2 doses, i.v. over 5 hours	-1 to +90
		MTX	15 mg/m^2 i.v.	+1
			10 mg/m^2 i.v.	+3, +6, +11
		MMF	2 g per day, oral (MRD) 3 g per day, oral (MUD)	+1 to +90
MMUD or Haplo-HSCT	Post-Cy-based (n=18)	Horse ATG	10 mg/kg in 2 doses, i.v. over 6 hours	-4 to -1
		Cy	50 mg/kg i.v. over an hour	+3, +4
		CsA	3 mg/kg in 2 doses, i.v. over 5 hours	+5 to +180
		MMF	3 g per day, oral	+5 to +90
Haplo-HSCT	*Ex vivo* TCRαβ and CD19 depletion (n=15)	transplant processing	-	-1
		Rituximab	100 mg/m^2 i.v. over 4 hours	-1
		Bortezomib	1.3 mg/m^2 subcutaneously	-5, -2, +2, +5
		Tocilizumab	8 mg/kg i.v. over an hour	-1
		Abatacept	10 mg/kg i.v. over an hour	-1, +7, +14, +28

Laboratory tests and flow cytometry

Samples of peripheral blood and BM were collected in EDTA tubes on days +30, +60, +90, and +180 after allo-HSCT. Flow cytometry was performed on a BD FACS Canto II (Becton Dickinson, USA) to define the CD4$^+$ and CD8$^+$ T memory subsets. Anti- CD4 PerCP-Cy5.5, anti- CD8 APC-Cy7, anti- CD197 PE-Cy7, anti-PD-1 PE, anti-CD28 APC, and anti-CD45RO FITC (Becton Dickinson, USA) were used to analyze the expression of surface markers. We identified T naïve and T stem cell memory (Tnv+Tscm) as CD45R0-CCR7+CD28+, T central memory (Tcm) as CD45R0+CCR7+CD28+, T transitional memory (Ttm) as CD45R0+CCR7-CD28+, T effector memory (Tem) as CD45R0+CCR7-CD28-, and T terminal effector (Tte) as CD45R0-CCR7-CD28-. The absolute and relative cell counts were obtained for analysis. Values for the control group were used as references. The control group comprised 10 healthy individuals with a median age of 29 years (range, 18–40 years; five males and five females).

Statistical analysis

All data analyses were conducted using R ver. 4.1 (R Core Team, Vienna, Austria). The Shapiro-Wilk criterion was used to check the normality of the distribution of variables. The Kruskal-Wallis test was used for nonparametric data analysis for three or more independent groups and the Mann-Whitney U-test for two independent samples. The Friedman criterion was used to analyze repeated measurements (dynamics). The chi-square test was performed to analyze contingency tables, and the exact Fischer test was used for 2 × 2 tables. Analysis of overall survival and relapse-free survival was performed using the Kaplan-Meyer method, and a log-rank test was used to compare survival curves.

Data are presented as median and interquartile intervals (the difference between the 1st and 3rd quartiles). Box-and-whisker diagrams indicate the median, 25th and 75th percentiles. Line graphs show the dynamics. Statistical significance was set at $P<0.05$.

RESULTS

Clinical results

All patients (n=65) achieved neutrophil engraftment (a sustained absolute neutrophil count of ≥ 500 cells/µL for 3 consecutive days) on day +21 (range, 9–47). Platelet engraftment (platelet count of ≥20000 cells per microliter without transfusions for at least 7 consecutive days) was registered in 59 patients. The median time for platelet engraftment was 19 days (range: 9–46 days).

CR and full donor chimerism were confirmed in all patients on day +30. Acute GVHD grades II–IV were diagnosed in 18/65 (27.7%) patients. The median time of acute GVHD onset was 87 days (range, 22-178). Steroid-refractory GVHD was diagnosed in 7/18 (38.9%) patients. Notably, in 5 (38.5%) patients who previously received ATG-based prophylaxis, steroid-refractory GVHD developed after donor lymphocyte transfusions due to mixed chimerism that appeared on days +65 to +157. No cases of mixed chimerism were observed in the Post-Cy group or the ex vivo T cell depletion group. However, there were no statistically significant differences in the groups' acute GVHD rates. The rate of acute GVHD was 40.6% for horse ATG prophylaxis, 11.1% after horse ATG with PT-Cy, and 20% after ex vivo T cell depletion.

Leukemia relapse after day +30 was diagnosed in 14/65 (21.5%) of patients. Relapse-free survival during 30 months was 41.6%. The relapse rates did not differ significantly after different GVHD prophylaxis regimens.

Nineteen patients died of relapse (n=7), steroid-refractory acute GVHD (n=4), infectious complications (n=4), and secondary graft failure (n=4). Thirty-month overall survival was 51.8%, and no significant differences were observed among the three groups.

Reconstitution of CD4+ and CD8+ T cells, different memory T cells

We compared the absolute cell counts of different T cells in peripheral blood on days +30, +60, +90, and +180 in patients after the ATG-based and ATG+Post-Cy regimens and *ex vivo* T cell depletion. The data are summarized in Table 4.

37

Table 4: Absolute count of different T cells in peripheral blood after allo-HSCT

| Day after allo-HSCT | T cell subsets | Absolute cell count per microliter, median (percentile 25–percentile 75) | | | P |
		ATG-based regimen	ATG+PT-Cy	*ex vivo* TCR αβ depletion	
+30	Total of CD4$^+$	111.88 (56.29-194.45)	22.89 (13.45-4764)	14.29 (5.34-16.70)	0.0001
	CD4$^+$ Tnv+scm	19.19 (5.47-55.00)	0.73 (0.25-2.87)	0.26 (0.08-0.34)	0.0001
	CD4$^+$ Tcm	23.27 (6.67-50.99)	5.43 (1.81-11.62)	5.03 (1.01-6.00)	0.002
	CD4$^+$ Ttm	46.65 (28.81-76.17)	10.46 (6.30-26.62)	7.36 (3.71-10.54)	0.0001
	CD4$^+$ Tem	1.23 (0.91-2.25)	0.8 (015-4.28)	0.08 (0.03-0.14)	0.0001
	CD4$^+$ Tte	1.12 (0.37-1.94)	0.26 (0.04-0.60)	0.13 (0.03-0.38)	0.001
	Total of CD8$^+$	51.20 (15.38-126.67)	26.76 (8.23-44.21)	3.12 (1.78-16.10)	0.001
	CD8$^+$ Tnv+scm	4.45 (1.62-7.00)	0.35 (0.11-0.57)	0.06 (0.04-0.15)	0.0001
	CD8$^+$ Tcm	0.76 (0.27-1.75)	0.22 (0.17-0.30)	0.12 (0.01-0.34)	0.001
	CD8$^+$ Ttm	14.25 (5.4-32.99)	8.73 (2.88-14.06)	1.0 (0.56-8.23)	0.001
	CD8$^+$ Tem	7.96 (2.03-39.58)	5.84 (0.77-14.58)	0.73 (0.41-5.23)	0.025
	CD8$^+$ Tte	9.46 (3.86-37.4)	3.62 (0.52-14.1)	0.71 (0.25-0.9)	0.0001
+60	Total of CD4$^+$	82.84 (57.58-227.82)	54.85 (45.74-84.92)	37.05 (15.92-197.18)	0.111
	CD4$^+$ Tnv+scm	16.24 (3.59-30.13)	2.92 (0.68-9.43)	0.73 (0.27-1.29)	0.001
	CD4$^+$ Tcm	17.38 (9.18-36.81)	17.16 (9.90-24.63)	8.17 (4.95-15.53)	0.178
	CD4$^+$ Ttm	44.55 (29.86-81.89)	31.61 (23.86-41.14)	22.74 (8.69-53.42)	0.039
	CD4$^+$ Tem	1.62 (0.86-8.33)	0.99 (0.27-3.38)	0.82 (0.18-55.71)	0.555
	CD4$^+$ Tte	0.46 (0.21-0.77)	0.13 (0.05-0.72)	0.23 (0.08-1.62)	0.329
	Total of CD8$^+$	99.54 (31.55-331.97)	71.56 (27.36-206.61)	27.15 (5.42-169.43)	0.153
	CD8$^+$ Tnv+scm	3.06 (1.86-5.73)	1.7 (0.84-3.83)	0.12 (0.03-0.22)	0.0001
	CD8$^+$ Tcm	0.99 (0.36-2.04)	0.78 (0.42-1.57)	0.11 (0.05-0.35)	0.001
	CD8$^+$ Ttm	20.87 (9.05-50.79)	13.52 (9.75-83.61)	4.77 (1.55-8.87)	0.006
	CD8$^+$ Tem	40.62 (9.51-133.23)	16.98 (3.4-88.29)	14.12 (1.43-135.30)	0.499
	CD8$^+$ Tte	23.96 (5.09-117.75)	15.52 (5.13-28.78)	7.37 (2.07-18.36)	0.122
+90	Total of CD4$^+$	184.64 (101.37-290.21)	55.51 (37.53-125.59)	62.44 (41.46-146.75)	0.019
	CD4$^+$ Tnv+scm	18.68 (6.95-45.89)	1.83 (1.25-3.37)	0.70 (0.32-4.76)	0.002
	CD4$^+$ Tcm	39.26 (18.92-52.98)	12.09 (6.21-36.04)	10.54 (1.05-16.82)	0.007
	CD4$^+$ Ttm	76.13 (47.28-159.32)	30.15 (26.39-62.52)	26.24 (19.51-49.66)	0.004
	CD4$^+$ Tem	7.57 (1.82-15.91)	2.49 (0.86-4.93)	3.8 (1.22-20.00)	0.230
	CD4$^+$ Tte	0.47 (0.22-1.59)	0.21 (0.08-0.45)	0.66 (0.06-5.35)	0.153
	Total of CD8$^+$	258.03 (185.71-684.00)	127.36 (25.47-507.58)	33.53 (23.20-104.10)	0.002
	CD8$^+$ Tnv+scm	4.56 (2.99-12.04)	2.11 (1.27-3.7)	0.34 (0.04-0.7)	0.0001
	CD8$^+$ Tcm	2.36 (0.72-5.74)	0.34 (0.15-4.36)	0.17 (0.05-0.81)	0.002
	CD8$^+$ Ttm	51.60 (36.32-115.87)	22.25 (6.88-179.53)	3.97 (0.44-8.78)	0.0001
	CD8$^+$ Tem	143.83 (33.19-275.20)	25.20 (4.64-215.07)	18.67 (5.36-65.04)	0.055
	CD8$^+$ Tte	78.10 (28.92-219.92)	48.93 (7.46-74.60)	8.66 (4.08-27.68)	0.002
+180	Total of CD4$^+$	255.19 (166.41-319.97)	141.49 (102.91-182.60)	183.80 (73.62-266.40)	0.105
	CD4$^+$ Tnv+scm	23.56 (6.76-45.14)	4.42 (2.58-9.31)	13.53 (4.78-75.13)	0.060
	CD4$^+$ Tcm	46.99 (24.23-62.66)	18.55 (14.80-27.00)	37.18 (17.15-44.94)	0.082
	CD4$^+$ Ttm	121.24 (97.19-164.90)	87.96 (69.43-148.19)	82.43 (45.24-87.57)	0.022
	CD4$^+$ Tem	11.38 (3.85-42.73)	3.46 (1.20-17.57)	4.86 (1.97-27.80)	0.455
	CD4$^+$ Tte	1.14 (0.38-4.04)	0.66 (0.17-1.35)	1.13 (0.29-5.31)	0.433
	Total of CD8$^+$	586.27 (360.56-922.28)	237.38 (99.90-484.39)	88.26 (67.23-198.27)	0.001
	CD8$^+$ Tnv+scm	10.76 (4.5-19.12)	6.73 (1.88-8.11)	4.79 (1.58-33.52)	0.273
	CD8$^+$ Tcm	3.07 (1.16-5.73)	0.74 (0.62-1.63)	1.41 (0.27-2.49)	0.129
	CD8$^+$ Ttm	83.85 (49.58-115.97)	37.40 (22.58-153.61)	21.01 (6.43-25.86)	0.0001
	CD8$^+$ Tem	264.67 (160.78-369.76)	81.59 (31.46-108.40)	47.66 (13.07-105.16)	0.008
	CD8$^+$ Tte	152.27 (55.59-307.35)	50.98 (25.35-158.40)	14.32 (10.62-42.93)	0.005

According to the obtained data, the short-term period after allo-HSCT (days +30, +60, +90) is characterized by significantly lower absolute numbers of Tnv+scm and Tcm in the peripheral blood of patients after ATG+Post-Cy-regimen or *ex vivo* T cell depletion than with ATG-based prophylaxis (p<0.05). The absolute numbers of Tnv+scm and Tcm did not differ on day +180 in the groups.

The recovery of the effector pool consisting of Ttm, Tem, and Tte differed among the groups. The absolute counts of Ttm, Tem, and Tte were lower on day +30 for the ATG+Post-Cy-regimen or *ex vivo* T cell depletion than for the ATG-based regimen (p<0.05). There were significant differences in the absolute cell counts of CD4+ and CD8+ Ttm during the follow-up period, and the counts of CD8+ Tem and CD8+ Tte were distinguished on day +180 and on days +90 – +180, respectively.

The recovery of T memory cell subsets is presented separately in the graphs for CD4+ and CD8+ cells (Figures 1 and 2, respectively).


Figure 1. – Reconstitution of CD4+ T memory cell subsets in peripheral blood in acute leukemia patients after allo-HSCT. A star denotes the significance level between two groups, * - p<0.05, ** - p<0.01, *** - p<0.001. Kruskal-Wallis exact p value for the significance for 3 and more independent groups.

Tnv+scm, Tcm, Ttm, Tem, and Tte belonged to CD4+ and were measured quantified at the posttransplant time points (+30, +60, +90, and +180 days) among the patients after horse ATG, horse ATG combined with PT-Cy, and *ex vivo* T cell depletion. Absolute cell counts in healthy donors were used as a reference. Significant differences between groups are indicated by *.

Figure 2. Reconstitution of CD8+ T memory cell subsets in peripheral blood in acute leukemia patients after allo-HSCT. A star was used for the significance level between two groups, * - p<0.05, ** - p<0.01, *** - p<0.001. Kruskal-Wallis exact p value for the significance for three and more independent groups.

Tnv+scm, Tcm, Ttm, Tem, and Tte belonged to CD8+ and were quantified at the posttransplant time points (+30, +60, +90, and +180 days) among the patients after horse ATG, horse ATG combined with PT-Cy, and *ex vivo* T cell depletion. Absolute cell counts in healthy donors were used as a reference. Significant differences between groups are indicated by *.

Dynamics of different memory T cells' recovery depended on GVHD prophylaxis

We also considered the influence of time on the dynamics of T cell recovery. All patients were subdivided into three groups by the immunosuppressive protocol, and analysis was conducted within each patient group, separately for the ATG group, ATG+PT-Cy, and *ex vivo* T cell depletion.

The dynamics of recovery of all T subsets (Tnv+scm, Tcm, and effector T cells) was different in the case of *ex vivo* TCR αβ depletion (p<0.05), whereas prophylaxis with ATG or ATG+Post-Cy was accompanied by significant changes in the pool of effector T cells (Figure 3).


Figure 3. Dynamics of T memory cell subsets recovery in patients after different GVHD prophylaxis.

Each line on the graph reflects the quantitative change in cells, separately for Tnv+scm, Tcm, Ttm, Tem, and Tte, over time for each patient group – separately for patients after horse ATG only (red), horse ATG combined with PT-Cy (green), and *ex vivo* T cell depletion (blue).

Reconstitution of BM resident T memory cell subsets in patients after allo-HSCT

We compared the relative cell counts in the BM of patients after different GVHD prophylaxis regimens on days +30, +60, +90, and +180. The relative counts of Tnv+scm, Tcm, Ttm, Tem, and Tte in the BM of the control group were used as a reference.

Reconstitution of Tnv+scm, Tcm, Ttm, Tem, and Tte did not differ after ATG, ATG+Post-Cy, and *ex vivo* T cell depletion during the follow-up period. However, in patients after allo-HSCT, the distribution of cellular subpopulations of BM is shifted toward the effector pool, whereas in healthy individuals, the BM is heterogeneous with the greatest number of naïve and stem memory cells. The distribution of BM T memory cell subsets, separately for CD4+ and CD8+, in patients after allo-HSCT compared that of healthy individuals is presented in Figures 4 and 5, respectively.


Figure 4. Distribution of BM CD4+ T memory cell subsets in patients after allo-HSCT and healthy individuals.

The graph shows the percentage of cell populations among CD4+ T cells for patients after allo-HSCT, separately for the horse ATG group, horse ATG combined with PT-Cy, *ex vivo* T cell depletion, and healthy controls.

41

Figure 5. Distribution of BM CD8$^+$ T memory cell subsets in patients after allo-HSCT and the healthy individuals

The graph shows the percentage of cell populations among CD8$^+$ T cells for patients after allo-HSCT, separately for the horse ATG group, horse ATG combined with PT-Cy, *ex vivo* T cell depletion, and healthy controls.

Impact of types of T memory cell recovery on the development of leukemia relapse after allo-HSCT

We compared the absolute numbers of Tnv+scm, Tcm, Ttm, Tem, and Tte in peripheral blood and the relative counts of BM resident T cells on day +30 in two patient groups. The first group comprised patients with durable CR after allo-HSCT (n=51), and the second group comprised patients who relapsed after day +30 (n=14). According to our data, reconstitution of memory T cell subsets in the peripheral blood and BM had no impact on the development of leukemia relapse after allo-HSCT (Table 5).

Impact of different T memory cells' recovery on development of acute GVHD

We compared the absolute number of T cells on day +30 between two patient groups. The first group comprised patients without acute GVHD (n=47), and the second group comprised patients with acute GVHD after day +30 (n=17). One patient was excluded from the analysis because of the development of acute GVHD on day +22.

The absolute number of CD8$^+$ Tnv+scm cells in peripheral blood on day +30 was significantly higher in the group with acute GVHD after day +30 (p=0.008), and the total count of CD8$^+$ T cells did not differ between the two groups. Therefore, ROC analysis was conducted to determine the cutoff for CD8$^+$ Tnv+scm in the peripheral blood on day +30. If the CD8$^+$ Tnv+scm count did not exceed 1.31 cells per, the probability of acute GVHD was 12.9% versus 46.2%, p=0.008.

No statistical differences were observed in the absolute counts of Tcm, Ttm, Tem, and Tte in the peripheral blood on day +30 between the two groups.

42

Table 5. Impact of different T memory cell counts on developing leukemia relapse after allo-HSCT

Subsets	Cell count on day +30 after allo-HSCT, median (percentile 25–percentile 75)		P
	Relapse after day +30	Durable CR after allo-HSCT	
CD4+ T cells of peripheral blood, absolute count			
Total of CD4+	57.62 (16.70-149.22)	40.26 (14.29-87.84)	0.549
CD4+ Tnv+scm	8.92 (0.58-16.10)	2.49 (0.32-21.22)	0.442
CD4+ Tcm	8.22 (5.03-30.52)	6.67 (3.99-20.78)	0.807
CD4+ Ttm	26.06 (10.42-30.81)	25.03 (7.29-46.65)	1.000
CD4+ Tem	0.40 (0.08-2.31)	0.56 (0.13-1.35)	0.813
CD4+ Tte	0.38 (0.20-0.55)	0.37 (0.06-1.12)	0.864
CD8+ T cells of peripheral blood, absolute count			
Total of CD8+	23.13 (4.99-36.85)	29.02 (10.58-80.25)	0.332
CD8+ Tnv+scm	0.55 (0.24-3.34)	1.13 (0.16-5.38)	0.661
CD8+ Tcm	0.17 (0.10-0.77)	0.33 (0.19-1.25)	0.108
CD8+ Ttm	5.64 (1.85-12.18)	9.59 (3.17-23.43)	0.323
CD8+ Tem	4.55 (0.54-10.27)	5.43 (1.20-20.97)	0.273
CD8+ Tte	3.08 (0.71-13.34)	4.32 (0.90-19.89)	0.558
CD4+ T cells of BM, %			
CD4+ Tnv+scm	7.17 (3.34-21.58)	8.52 (3.08-14.96)	0.988
CD4+ Tcm	15.15 (11.15-19.13)	14.10 (8.02-24.71)	0.876
CD4+ Ttm	62.31 (53.59-72.34)	52.98 (46.81-64.74)	0.379
CD4+ Tem	3.17 (1.06-7.77)	2.22 (1.52-4.77)	0.957
CD4+ Tte	1.14 (0.92-5.49)	1.85 (0.62-6.32)	0.869
CD8+ T cells of BM,%			
CD8+ Tnv+scm	2.29 (1.24-4.78)	4.47 (1.96-10.75)	0.073
CD8+ Tcm	1.13 (0.82-2.18)	1.66 (0.75-3.31)	0.514

DISCUSSION

The immunological aspects of allo-HSCT are based on the formation of GVL without GVHD. Studies have described the phenomenon of GVL [26-29]. The role of T cells, especially CD4[+] T cells, in the mechanism of GVL was discussed in 1997 by Barrett [41]. However, much has been clarified since then, and the role of other immune cells such as dendritic cells or NK has been shown. The key aspect of developing GVL still belongs to T cells because of their ability to implement pathogen-specific immunologic effects, including anti-leukemic effects[42,43]. This phenomenon is known as adaptive immunity, in which the main participants are memory cells [44].

A distinctive feature of true memory cells (Tscm and Tcm) is their ability to proliferate in the BM without the need for permanent antigenic stimulation and a prompt reaction against the antigen[30,31]. We hypothesized that donor memory T cells, mostly Tcm, could be a key subset responsible for implementing the anti-leukemic effect shortly after allo-HSCT. The same effect is observed after chimeric antigen receptor (CAR) T cell therapy when long-lasting circulating Tcm provides durable remission[32]. However, our data demonstrate that low numbers of Tcm are in the peripheral blood of patients on days +30 to +90 after allo-HSCT, particularly in the case of the addition of PT-Cy for GVHD prophylaxis or when using a manipulated graft with *ex vivo* T cell depletion. There was also no difference in the absolute count of circulating Tcm in patients in CR or those who relapsed after allo-HSCT, which questioned the ability of GVL formation only with circulating donor Tcm. Moreover, a shift toward the prevalence of the effectors and reduced number of naïve and central memory cells in the BM of patients after allo-HSCT could reflect the phenomenon of homeostatic proliferation rather than the formation of antitumor immunity [33, 34].

Tcm is considered the only pool providing immune recovery without the risk of inducing GVHD[35]. This phenomenon is possible because of the ability of Tcm to proliferate and generate a pool of Tem and Tte that subsequently react against the antigen. However, transplantation of selective T effector cells fails because of the inability of Tem and Tte to proliferate and self-regenerate[36,37]. Some studies have demonstrated that naïve T cells and memory T stem cells are the only subpopulations that provide full immune recovery, including generation of effectors and formation of immunological memory[38]. Therefore, we propose that a higher count of Tnv+scm early after allo-HSCT and its prompt recovery, together with the generation of Tcm, provide essential anti-leukemia effects.

However, other studies have shown that alloreactive T cells that cause severe GVHD are naïve T cells, due to the ability of these cells to migrate and proliferate in secondary lymphoid tissues[39,40]. The maximum count of these naïve-like alloreactive T cells is observed on days +3 to +6 after allo-HSCT, explaining the use of PT-Cy to prevent GVHD[18,39,40]. The mechanism of ATG is less selective than that of PT-Cy and shows the possibility of total lymphodepletion[20,21]. Our data demonstrate that ATG alone failed to deplete naïve T cell compartment compared with PT-Cy or *ex vivo* T cell depletion, which seems to be an immunological reason for mixed chimerism and the next requirement of donor lymphocyte infusion in this patient cohort. This finding can explain the high frequency of GVHD in patients after fully matched allo-HSCT with ATG-based prophylaxis (40.6% vs. 11.1% after ATG+PT-Cy and 20% after *ex vivo* T cell depletion) and 38.5% steroid-refractoriness.

The role of naïve T cells as GVHD triggers has been discussed[39,40], and together with our results, and considering the depletion of these cells as an effective way to prevent GVHD seems appropriate. According to our data, depletion of Tnv+scm by PT-Cy is comparable in quantitative cellular assessment and the rate of acute GVHD to the effect of *ex vivo* T cell depletion. However, regardless of GVHD risk, the reconstitution of this cell population is a key aspect for the recovery of whole T cell immunity and the formation of immunological memory [38]. Despite the similar immunoablative effects in the study groups with PT-Cy and *ex vivo* T depletion, the dynamics of T cell recovery significantly differed. The reconstitution involving Tnv+scm, Tcm, and the effector pool (Ttm, Tem, Tte) occurs after *ex vivo* TCR αβ depletion, and the effect of PT-Cy seems to be more selective than that and affects only the effector pool. However, differences in the dynamics of T cell

44

recovery in the study groups had no influence on clinical outcomes. The rates of acute GVHD and leukemia relapse were comparable after ATG+PT-Cy and *ex vivo* T cell depletion.

CONCLUSION

In summary, we can conclude that the reconstitution of T cell immunity depends on many factors. In this research, we analyzed the impact of GVHD prophylaxis and demonstrated that its choice might determine future events such as acute GVHD.

CONFLICT OF INTEREST

The authors have no relevant conflicts of interest to disclose.

REFERENCES

1. Mehta RS, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence. 2016; 7(8): 901-16.
2. Huttunen P, Taskinen M, Siitonen S, et al. Impact of very early CD4+/CD8+ T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2015; 62(3):522–8.
3. Ogonek J, Kralj Juric M, Ghimire S, et al. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2016; 7:507.
4. Jiménez M, Ercilla G, Martínez C. Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens. Leukemia. 2007; 21(8): 1628–1637.
5. Bosch M, Dhadda M, Hoegh-Petersen M, et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy. 2012; 14(10):1258-75.
6. Retière C, Willem C, Guillaume T, et al. Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Oncotarget. 2018; 9(14): 11451–11464.
7. Krenger W, Blazar BR, Holländer GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood. 2011; 117(25): 6768–6776.
8. Kaech SM, Hemby S, Kersh E, et al. Molecular and functional profiling of memory CD8 T cell differentiation. Cell. 2002; 111(6):837-51.
9. Zheng H, Matte-Martone C, Jain D, et al. Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia. J Immunol. 2009;182(10):5938-48.
10. Huang W, Chao NJ. Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease. Hematol Oncol Stem Cell Ther. 2017; 10(4):211-219.
11. MacVittie TJ, Bennett AW, Cohen MV, et al. Immune cell reconstitution after exposure to potentially lethal doses of radiation in the nonhuman primate. Health Phys. 2014;106(1):84-96.
12. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997;89(10):3700-7
13. Chung B, Barbara-Burnham L, Barsky L, et al. Radiosensitivity of thymic interleukin-7 production and thymopoiesis after bone marrow transplantation. Blood. 2001; 98(5):1601-6.
14. Fletcher AL, Lowen TE, Sakkal S, et al. Ablation and regeneration of tolerance-inducing medullary thymic epithelial cells after cyclosporine, cyclophosphamide, and dexamethasone treatment. J Immunol. 2009; 183(2):823-31.
15. Turner BE, Collin M, Rice AM. Reduced intensity conditioning for hematopoietic stem cell transplantation: has it achieved all it set out to? Cytotherapy. 2010; 12(4):440-54.
16. Jiménez M, Martínez C, Ercilla G, et al. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation. Exp Hematol. 2005; 33(10):1240-8.
17. Bahceci E, Epperson D, Douek DC, et al. Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism. Br J Haematol. 2003; 122(6):934-43.
18. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14(6):641-50.
19. Al-Homsi AS, Roy TS, Cole K, et al. Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015; 21(4):604-11.
20. Servais S, Menten-Dedoyart C, Beguin Y, et al. Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. PLoS One. 2015; 10(6):e0130026.

21. Storek J, Mohty M, Boelens JJ. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015; 21(6):959-70.

22. Battipaglia G, Labopin M, Kröger N, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019; 134(11):892-899.

23. Nykolyszyn C, Granata A, Pagliardini T, et al. Posttransplantation cyclophosphamide vs antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020; 55(2):349-355.

24. Pagliardini T, Harbi S, Fürst S, et al. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. Bone Marrow Transplant. 2019; 54(7):1067-1076.

25. Saad A, Lamb L. Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future. Bone Marrow Transplant. 2017; 52(9): 1241-1248.

26. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300(19):1068-73.

27. Falkenburg JHF, Jedema I. Graft versus tumor effects and why people relapse. Hematology Am Soc Hematol Educ Program. 2017;2017(1):693-698.

28. Chang YJ, Zhao XY, Huang XJ. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Front Immunol. 2018; 9:3041.

29. Ringdén O, Karlsson H, Olsson R, et al. The allogeneic graft-versus-cancer effect. Br J Haematol. 2009;147(5):614-33.

30. Mueller SN, Gebhardt T, Carbone FR, et al. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol. 2013; 31: 137–61.

31. Becker TC, Coley SM, Wherry EJ, et al. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol. 2005; 174 (3): 1269–73.

32. Blaeschke F, Stenger D, Kaeuferle T, et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. Cancer Immunol Immunother. 2018; 67(7): 1053–1066.

33. Jameson SC. T cell homeostasis: keeping useful T cells alive and live T cells useful. Semin Immunol. 2005; 17(3): 231–7.

34. Bourgeois C, Bourgeois C, Stockinger B. T cell homeostasis in steady state and lymphopenic conditions. Immunol Lett. 2006; 107(2): 89–92.

35. Huang W, Mo W, Jiang J, et al. Donor Allospecific CD44high Central Memory T Cells Have Decreased Ability to Mediate Graft-vs.-Host Disease. Front Immunol. 2019;10:624.

36. Wherry EJ, Teichgräber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003; 4(3):225–34.

37. Graef P, Buchholz VR, Stemberger C, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity. 2014; 41(1):116–26.

38. Cieri N, Oliveira G, Greco R, et al. Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood. 2015;125(18): 2865–74.

39. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106(3):1113–22.

40. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, et al. Leukocyte migration and graft-versus-host disease. Blood. 2005;105(11): 4191–99.

41. Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells. 1997;15(4):248-58.

42. Dickinson AM, Norden J, Li S, et al. Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. Front Immunol. 2017; 8:496.

43. Falkenburg JH, Warren EH. Graft versus leukemia reactivity after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(1 Suppl):S33-8.

44. Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010; 125(2 Suppl 2): S33-40.